Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration

Published:2021-05-18 Issue:5 Volume:4 Page:e2110456
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Hutchinson Nora¹,Carlisle Benjamin¹,Doussau Adelaide¹,Bosan Rafia¹,Gumnit Eli¹,MacPherson Amanda¹,Fergusson Dean A.²³,Kimmelman Jonathan¹

Affiliation:

1. Studies of Translation, Ethics, and Medicine, Biomedical Ethics Unit, McGill University, Montreal, Québec, Canada

2. Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

3. Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2779935/hutchinson_2021_oi_210314_1620356495.04759.pdf

Reference32 articles.

1. Estimated research and development investment needed to bring a new medicine to market, 2009-2018.;Wouters;JAMA,2020

2. Research and development spending to bring a single cancer drug to market and revenues after approval.;Prasad;JAMA Intern Med,2017

3. Clinical development success rates for investigational drugs.;Hay;Nat Biotechnol,2014

4. Can the pharmaceutical industry reduce attrition rates?;Kola;Nat Rev Drug Discov,2004

5. Examining trends in cost and clinical benefit of novel anticancer drugs over time.;Saluja;J Oncol Pract,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012–2022;Asia-Pacific Journal of Clinical Oncology;2024-06-24

2. Alternative evidence in drug development and regulatory science;Comprehensive Precision Medicine;2024

3. Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016–2021: An observational study;PLOS Medicine;2023-12-12

4. Timing for First-in-Minor Clinical Trials of New Cancer Drugs;The Journal of Pediatrics;2023-12

5. Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study;Scientific Reports;2023-09-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3